Skip to main content
News Krawitz 02.2022
© Colourbox

News categories: Publication

AI-driven facial analysis improves diagnosis

Researchers at the University of Bonn use artificial intelligence (AI) to detect rare diseases even more accurately

Rare genetic diseases can sometimes be recognized through facial features, such as characteristically shaped brows, nose or cheeks. Researchers of the Cluster of Excellence ImmunoSensation2 have now trained software that uses portrait photos to better diagnose such diseases. The study has now been published in the journal "Nature Genetics".

Many sufferers of rare diseases endure an odyssey until the correct diagnosis is made. "The goal is to detect such diseases at an early stage and initiate appropriate therapy as soon as possible," says Prof. Dr. Peter Krawitz from the Institute for Genomic Statistics and Bioinformatics (IGSB) at the University Hospital Bonn. The researcher is a member of the Cluster of Excellence ImmunoSensation2 and the Transdisciplinary Research Area "Modelling" at the University of Bonn.

The majority of rare diseases are genetic. The underlying hereditary mutations often cause varying degrees of impairment in different areas of the body. In most cases, these hereditary changes are also expressed by characteristic facial features: for example, because eyebrows, the base of the nose or the cheeks are shaped in a distinctive way. However, this varies from disease to disease. Artificial intelligence (AI) uses these facial characteristics, calculates the similarities, and automatically links them to clinical symptoms and genetic data of patients. "The face provides us with a starting point for diagnosis," says Tzung-Chien Hsieh of Krawitz's team. "It is possible to calculate what the disease is with a high degree of accuracy."

The AI system "GestaltMatcher" described in the current publication is a continued development of "DeepGestalt", which the IGSB team trained with other institutions a few years ago. While DeepGestalt still required about ten non-related affected persons as a reference for training, its successor "GestaltMatcher" requires significantly fewer patients for feature matching. This is a great advantage in the group of very rare diseases, where only a few patients are reported worldwide. Furthermore, the new AI system also considers similarities with patients who have also not yet been diagnosed, and thus combinations of characteristics that have not yet been described. GestaltMatcher therefore also "recognizes" diseases that were previously unknown to it and suggests diagnoses based on this. "This means we can now classify previously unknown diseases, search for other cases and provide clues as to the molecular basis," says Krawitz.

The team used 17,560 patient photos, most of which came from digital health company FDNA, which the research team worked with developing the web service through which the AI can be used. Around 5,000 of the photos and patient data were contributed by the research team at the Institute of Human Genetics at the University of Bonn, along with nine other university sites in Germany and abroad. The researchers focused on disease patterns that were as diverse as possible. They were able to consider a total of 1,115 different rare diseases. "This wide variation in appearance trained the AI so well that we can now diagnose with relative confidence even with only two patients as our baseline at best, if that's possible," Krawitz says.

"We are very happy to finally have a phenotype analysis solution for the ultra-rare cases, which can help clinicians solve challenging cases, and researchers to progress rare disease understanding," says Aviram Bar-Haim of FDNA Inc. in Boston, USA. In Germany, too, the application in doctors' offices, for example, is not far off, adds Krawitz. Doctors can already use their smartphones to take a portrait photo of a patient and use AI to make differential diagnoses, he says. "GestaltMatcher helps the physician make an assessment and complements expert opinion."

Peter Krawitz and his team turned over the data they collected themselves to the non-profit Association for Genome Diagnostics (AGD), to provide researchers with access. "The GestaltMatcher Database (GMDB) will improve the comparability of algorithms and provide the basis for further development of artificial intelligence for rare diseases, including other medical image data such as X-rays or retinal images from ophthalmology," Krawitz says.


Participating institutions and funding

In addition to the Institute for Genomic Statistics and Bioinformatics and the Institute of Human Genetics of the University Hospital Bonn, the Charité-Universitätsmedizin Berlin, the universities of Greifswald, Tübingen, Düsseldorf, Lübeck, Heidelberg, the Technical University of Munich as well as universities from South Africa, France, the USA and Norway were involved. The study was mainly funded by the German Research Foundation (DFG).


Publication

Tzung-Chien Hsieh et al: GestaltMatcher: Overcoming the limits of rare disease matching using facial phenotypic descriptors, Nature Genetics, DOI: 10.1038/s41588-021-01010-x


Contact

Prof. Dr. med. Dipl. Phys. Peter Krawitz

Institute for Genomic Statistics and Bioinformatics (IGSB)

University Hospital Bonn

Phone: +49 228 287 14799

Email: pkrawitz@uni-bonn.de

Related news

Neurons - generated through the differentiation of induced neural stem cells (iNSCs) derived from blood.

News categories: Publication

Researchers Transform Old Blood Cells into Young Brain Cells

—Researchers from the University Hospital of Bonn and the University of Bonn have succeeded in dramatically rejuvenating human cells in a test tube. To do so, they directly reprogrammed red blood cell precursors into stem cells from which neurons can be derived. During this process, the molecular clocks that indicate a cell’s age were reset. For example, blood cells from an 80-year-old were transformed into stem cells with a molecular age of less than 20 years. The results have been published in the journal Aging Cell.
View entry
Dr. Robert Hüneburg, Dr. Anne-Sophie Layritz, and Nicola Reents (from left) - conducted a survey and found that fewer than one in ten people with Lynch syndrome take Acetylsalicylic acid for cancer prevention – despite a high level of openness to new preventive approaches.

News categories: Publication

Aspirin Rarely Used for Colorectal Cancer Prevention

—According to international studies, taking Acetylsalicylic acid daily can protect people with Lynch syndrome from developing colorectal cancer – even at low doses. Researchers from the University Hospital Bonn (UKB), the University of Bonn, and the Center for Integrated Oncology (CIO) Bonn, in collaboration with the self-help organization SemiColon, have now found that these scientific findings have so far been insufficiently incorporated into clinical practice. The results of the LYNX study have now been published as a letter in the journal The Lancet Gastroenterology & Hepatology.
View entry
Smartphone-based retinal imaging in clinical practice in India: - The image was taken during a collaborative project between University Hospital Bonn (UKB) and Sankara Eye Foundation India on smartphone-based telemedical screening for diabetic retinopathy.

News categories: Publication

Smartphones as Retinal Cameras: New Opportunities for Global Eye Care

—Smartphones could play an important role in the early detection of eye diseases, including in settings where specialized ophthalmic infrastructure is limited. An international team of experts led by the UKB and the University of Bonn has comprehensively reviewed the current global landscape of smartphone-based fundus imaging. The researchers highlight the technical and clinical possibilities that already exist today, identify the limitations of these methods, and outline the conditions that must be met so that smartphone-based retinal imaging can be more widely integrated into screening.
View entry

Back to the news overview